AU2013320261A1 - Treatment for rheumatoid arthritis - Google Patents

Treatment for rheumatoid arthritis Download PDF

Info

Publication number
AU2013320261A1
AU2013320261A1 AU2013320261A AU2013320261A AU2013320261A1 AU 2013320261 A1 AU2013320261 A1 AU 2013320261A1 AU 2013320261 A AU2013320261 A AU 2013320261A AU 2013320261 A AU2013320261 A AU 2013320261A AU 2013320261 A1 AU2013320261 A1 AU 2013320261A1
Authority
AU
Australia
Prior art keywords
antibody
administered
dose
csf
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013320261A
Other languages
English (en)
Inventor
Stefan HAERTLE
Stephane Leclair
Amgad SHEBL
Stefan Steidl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of AU2013320261A1 publication Critical patent/AU2013320261A1/en
Priority to AU2016250388A priority Critical patent/AU2016250388B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2013320261A 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis Abandoned AU2013320261A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016250388A AU2016250388B2 (en) 2012-09-20 2016-10-26 Treatment for rheumatoid arthritis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
EP12185235.4 2012-09-20
US201261703871P 2012-09-21 2012-09-21
US61/703,871 2012-09-21
PCT/EP2013/069501 WO2014044768A1 (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016250388A Division AU2016250388B2 (en) 2012-09-20 2016-10-26 Treatment for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
AU2013320261A1 true AU2013320261A1 (en) 2015-04-09

Family

ID=46963526

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013320261A Abandoned AU2013320261A1 (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis
AU2016250388A Ceased AU2016250388B2 (en) 2012-09-20 2016-10-26 Treatment for rheumatoid arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016250388A Ceased AU2016250388B2 (en) 2012-09-20 2016-10-26 Treatment for rheumatoid arthritis

Country Status (22)

Country Link
US (4) US20150246969A1 (enExample)
EP (3) EP3916013A1 (enExample)
JP (4) JP2015533806A (enExample)
KR (4) KR20230041086A (enExample)
CN (2) CN104995210A (enExample)
AU (2) AU2013320261A1 (enExample)
BR (1) BR112015006189B1 (enExample)
CL (2) CL2015000696A1 (enExample)
CR (1) CR20150153A (enExample)
DO (1) DOP2015000070A (enExample)
EA (1) EA031489B1 (enExample)
HK (1) HK1208231A1 (enExample)
IL (1) IL237554B (enExample)
IN (1) IN2015KN00657A (enExample)
MA (1) MA37946B1 (enExample)
MX (2) MX382937B (enExample)
MY (1) MY175388A (enExample)
PE (1) PE20151079A1 (enExample)
PH (1) PH12015500591A1 (enExample)
SG (2) SG11201501595YA (enExample)
UA (1) UA117228C2 (enExample)
WO (1) WO2014044768A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
RU2714919C2 (ru) * 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
WO2015138638A1 (en) * 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
US11173208B2 (en) * 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
DK3328887T3 (da) 2016-09-19 2021-09-20 I Mab Biopharma Hangzhou Co Ltd Anti-GM-CSF antistoffer og anvendelser deraf
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100408229B1 (ko) 1996-10-04 2003-12-01 암겐 인코포레이티드 Ｍｐｌ 리간드를 함유하는 제약학적 조성물
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
ES2918209T3 (es) * 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
CA2618068C (en) 2005-08-05 2016-02-16 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
US20080206241A1 (en) * 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
CA2682406A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2008122415A1 (en) 2007-04-05 2008-10-16 Sandoz Ag Stable aqueous g-csf formulations
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP3381471B1 (en) * 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
US20120116059A1 (en) * 2009-05-05 2012-05-10 Morphosys Ag Treatment For M Treatment For Multiple Sclerosis
ES2432160T3 (es) 2009-12-31 2013-12-02 Arven Ilac Sanayi Ve Ticaret A.S. Procedimiento novedoso para preparar G-CSF (factor estimulante de colonias de granulocitos)
SG184355A1 (en) * 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗

Also Published As

Publication number Publication date
US20180230208A1 (en) 2018-08-16
UA117228C2 (uk) 2018-07-10
IL237554B (en) 2019-12-31
JP2022169709A (ja) 2022-11-09
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (en) 2014-03-27
PH12015500591B1 (en) 2015-05-11
US10913792B2 (en) 2021-02-09
EP3345923A1 (en) 2018-07-11
CN109999195A (zh) 2019-07-12
IL237554A0 (en) 2015-04-30
MX2021006111A (es) 2021-07-07
EA201590359A1 (ru) 2015-08-31
IN2015KN00657A (enExample) 2015-07-17
BR112015006189B1 (pt) 2022-04-05
AU2016250388B2 (en) 2018-07-19
PE20151079A1 (es) 2015-08-07
EP3916013A1 (en) 2021-12-01
AU2016250388A1 (en) 2016-11-17
EA031489B1 (ru) 2019-01-31
EP2897977A1 (en) 2015-07-29
US20150246969A1 (en) 2015-09-03
US20240417455A1 (en) 2024-12-19
SG10201803778PA (en) 2018-06-28
CN104995210A (zh) 2015-10-21
PH12015500591A1 (en) 2015-05-11
MX382937B (es) 2025-03-13
CA2884124A1 (en) 2014-03-27
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
CL2015000696A1 (es) 2015-10-23
KR20150056846A (ko) 2015-05-27
HK1208231A1 (en) 2016-02-26
KR20220028177A (ko) 2022-03-08
US20210130451A1 (en) 2021-05-06
JP2018138551A (ja) 2018-09-06
KR20240091288A (ko) 2024-06-21
MX2015003644A (es) 2015-09-25
JP2015533806A (ja) 2015-11-26
MA37946B1 (fr) 2018-09-28
BR112015006189A2 (pt) 2019-11-26
DOP2015000070A (es) 2015-08-16
JP2024156992A (ja) 2024-11-06
MA37946A1 (fr) 2018-01-31
CR20150153A (es) 2015-09-14
CL2018000933A1 (es) 2018-07-20

Similar Documents

Publication Publication Date Title
US20240417455A1 (en) Treatment for rheumatoid arthritis
JP6554155B2 (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
JP2024001125A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
US20200231666A1 (en) Treatment paradigm
CA2884124C (en) Treatment for rheumatoid arthritis
JP7132256B2 (ja) 関節リウマチの治療
EP4139353A1 (en) Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease
HK40064997A (en) Treatment for rheumatoid arthritis with anti-gm-csf antibody
NZ744721A (en) Treatment for rheumatoid arthritis
NZ744721B2 (en) Treatment for rheumatoid arthritis

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted